Trials / Completed
CompletedNCT03710824
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | diagnosed IPF patients initiating treatment with nintedanib |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2023-02-22
- Completion
- 2023-02-22
- First posted
- 2018-10-18
- Last updated
- 2024-07-31
- Results posted
- 2024-07-31
Locations
10 sites across 1 country: Greece
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03710824. Inclusion in this directory is not an endorsement.